Why the study?
Do adiponectin gene variants predict the risk of CAD and T2DM in European subjects?
Do adiponectin gene variants predict the risk of CAD and T2DM in European subjects?
Adiponectin gene variants are poor independent markers for the development of T2DM and CAD, with their influence likely depending on complex gene-gene or gene-environment interactions.
No takes yet. Share an insight, caveat, or question.
Adiponectin variants should not guide T2DM or CAD risk assessment; leaves open gene-environment interactions for prospective study.
Gable et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: